Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02558374 · ClinicalTrials.gov registry record · Phase 3
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
A Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 708
- Enrollment target
- 1
- Study location
NCT02558374: Completed Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Aerie Pharmaceuticals.
NCT02558374 is a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 708 participants, above the 265-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (167% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02558374, a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 708 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution.
Primary Outcome
The primary efficacy outcome is mean IOP
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AR-13324 Ophthalmic Solution 0.02%
- DRUG Timolol Maleate Ophthalmic Solution 0.5% BID
Study Locations (1)
New Jersey
- Aerie Pharmaceuticals - Bedminster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 708 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
What the finished NCT02558374 record still lists
NCT02558374 is an interventional study that assigns participants to a tested intervention. The registered 708 participants enrollment target is mid-sized for trials with a published cap, above the 265-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (167% higher).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02558374 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT02558374 about?
NCT02558374 is a clinical study titled "Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension". To evaluate ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution.
What is the current status of trial NCT02558374?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 708 participants. The study started on 2015-09. Estimated completion is 2016-12.
What conditions does trial NCT02558374 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT02558374?
The interventions under investigation include: Placebo (OTHER), AR-13324 Ophthalmic Solution 0.02% (DRUG), Timolol Maleate Ophthalmic Solution 0.5% BID (DRUG).
Who is sponsoring clinical trial NCT02558374?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02558374 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02558374's enrollment target sits among peer trials
708 3rd of 54 higher than 52 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia